Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

• Main Authors: Tammy Jiang (Author), Mathura Shanmugasundaram (Author), Ivan Bozin (Author), Mark S Freedman (Author), James B Lewin (Author)
• Format: Book
• Published: Becaris Publishing Limited, 2024-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Aim: Diroximel fumarate (DRF), ozanimod (OZA) and interferon beta-1a (IFN) are disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus OZA and IFN. We compared DRF versus OZA and DRF versus IFN using matching-adjusted indi...